ARS Pharmaceuticals vs Zevra Therapeutics
SPRY and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SPRY and ZVRA compare
Zevra Therapeutics is the larger company, worth 1.4 times as much as ARS Pharmaceuticals ($539M against $387M).
Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −14.5% for ARS Pharmaceuticals).
Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −164% at ARS Pharmaceuticals.
Zevra Therapeutics scores higher on the StockData Score (15 against 9 for ARS Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SPRY | ZVRA |
|---|---|---|
| Size and price | ||
| Market cap | $387M | $539M |
| Share price | $3.89 | $9.08 |
| Change, 1 year | −56.5% | −3.4% |
| Change, 5 years | −52.7% | 8.1% |
| Beta (5Y) | 1.42 | 0.86 |
| Employees | 158 | 61 |
| StockData Score | ||
| Total score | 9 | 15 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 9.8× |
| P/S | 3.2× (better) | 4.0× |
| P/B | – | 2.5× |
| EV/EBITDA | – | 3.8× |
| P/FCF | – | 16.5× |
| FCF yield | −47.3% | 6.1% (better) |
| Fair value | – | $25.61 |
| Margin of safety | – | 64.5% |
| Growth | ||
| Revenue growth (TTM) | −14.5% | 119% (better) |
| Revenue growth, 5Y average | – | 51.6% |
| Net income growth (TTM) | – | 2104% |
| Profitability | ||
| Gross margin | – | 95.5% |
| Operating margin | −161% | 60.5% (better) |
| Net margin | −164% | 42.8% (better) |
| FCF margin | −150% | 24.0% (better) |
| Return on equity | −295% | 34.8% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | – | −2.64 |
| Interest coverage | – | 14.4× |
| Current ratio | 3.25 | 5.17 (better) |
| Altman Z-score | −3.05 | 4.22 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.2% | 78.5% |
| Held by insiders | 46.7% | 1.2% |
| Insider net buying, 12 months | −$284K (better) | −$2.5M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.9% | 11.2% |
Go deeper
- SPRY stock overview
- SPRY income statement
- SPRY valuation and score
- ZVRA stock overview
- ZVRA income statement
- ZVRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.